Advances and challenges in hereditary cancer pharmacogenetics (Q38948499)

7 September 2017

1 reference

title

Advances and challenges in hereditary cancer pharmacogenetics (English)

1 reference

7 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27603572%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Anneke Nina Werk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27603572%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

7 September 2016

1 reference

Expert Opinion on Drug Metabolism & Toxicology

7 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27603572%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27603572%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27603572%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

73-82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27603572%20AND%20SRC:MED&resulttype=core&format=json

Translating neoadjuvant therapy into survival benefits: one size does not fit all.

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Targeted Therapy for Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Methylation pharmacogenetics: thiopurine methyltransferase as a model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Pharmacogenetics of ATP-binding cassette transporters and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

OCT1 and imatinib transport in CML: is it clinically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

MicroRNAs and their relevance to ABC transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2017.1233965

10.1080/17425255.2017.1233965

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27603572%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27603572%20AND%20SRC:MED&resulttype=core&format=json